Client & Alumni News

OraSure to acquire HIV diagnostic testing company in $31 million deal

OraSure Technologies, Inc. plans to acquire UrSure, a privately held Boston-based company whose products measure patient adherence to HIV medications, including preexposure prophylaxis or PrEP, the daily medication to prevent the virus.“The addition of UrSure to OraSure’s portfolio complements our work with HIV diagnostics and strengthens OraSure’s position as a global leader among public health-focused diagnostic companies in the HIV field,” said Stephen Tang, OraSure’s president and CEO. “We are now able to offer a product line that covers the spectrum from screening to treatment adherence.” Via Lehigh Valley Business, The Morning Call